Pricing Log in Create free account
Saturday 10 October 2026 Export all ABBV data to Excel Powerpack

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

276.47 4.05 +1.49%
Market cap
$481.4B
P/E
78.1×
Fwd P/E
27.8×
Dividend yield
3.10%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

AbbVie Inc. (ABBV) SEC filings, changes and red flags

Red flags

No red flags have been raised by AbbVie Inc.’s filings on file.

Filings

Form Period Filed What it reports Flags
8-K Oct 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 3, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 18, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 4, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 18 added · 2 removed · 32 modified
P2I1A: no comparison — the Item was not found
8-K Jul 31, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 18, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 8, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 4, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 24, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 4 added · 7 removed · 51 modified
1A: 11 added · 22 modified
7: 39 added · 41 removed · 35 modified
8-K Feb 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 31, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 11, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.